EUCTR2009-013131-38-DE
Active, not recruiting
Not Applicable
An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years. - A/H1N1 Immunogenicity and safety in infants, children and adolescents
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Baxter Innovations GmbH
- Enrollment
- 341
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject’s parent(s) / legal guardian(s) provide(s) written informed consent (according to national law);
- •Subject provides written assent to the study according to age and capacity of understanding;
- •Subject is 9 to 17 years (Stratum A), 3 to 8 years (Stratum B), 12 to 35 months (Stratum C) or, 6 to 11 months of age (Stratum D) at the time of screening;
- •Subject was born at full term of pregnancy (? 37 weeks) with a birth weight ? 2 kg (Strata C and D);
- •Subject / parent(s) / legal guardian(s) understand(s) the nature of the study and is / are willing to comply with the requirements of the protocol (e.g. return for follow\-up visits, completion of the subject diary);
- •If female of childbearing potential, subject presents with a negative urine pregnancy test within 24 hours prior to the first vaccination and agrees to employ adequate birth control measures for the duration of the study;
- •Subject is generally healthy, as determined by the investigator’s clinical judgment through collection of medical history and the performance of a physical examination;
- •Subject is physically and mentally capable of participating in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
Exclusion Criteria
- •Subject has participated in another clinical study involving an investigational drug, biological product or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an investigational drug, biological product or device during the course of this study;
- •Subject has a history of exposure to A/H1N1/California/07/2009 virus or a history of vaccination with A/H1N1/California/07/2009 antigen or a closely related influenza virus antigen;
- •Subject has any inherited or acquired immune deficiency;
- •Subject currently has or has a recent history of significant neurological, cardiovascular or pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder ;
- •Subject has a history of testing positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg) or Hepatitis C Virus (HCV) No confirmatory testing for previous infection with these viruses will be conducted as part of this clinical study;
- •Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response. Such treatment includes, but is not limited to: systemic or high dose inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic drugs;
- •Subject has a history of severe allergic reactions or anaphylaxis;
- •Subject has a rash, dermatologic condition or tattoos which might interfere with injection site reaction rating;
- •Subject has received a blood transfusion or immunoglobulins within 90 days of study entry;
- •Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years. - A/H1N1 Immunogenicity and safety in infants, children and adolescentsA/H1N1, Immunogenicity and Safety in Infants, Children and Adolescents, aged 6 months to 17 YearsMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-013131-38-ATBaxter Innovations GmbH341
Active, not recruiting
Not Applicable
A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above - NDEvaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and AboveMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaEUCTR2009-013904-30-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
Active, not recruiting
Not Applicable
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 VaccineEUCTR2008-005133-30-ATBaxter Innovations GmbH230
Active, not recruiting
Not Applicable
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 VaccineH5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years.MedDRA version: 9.1Level: LLTClassification code 10059430Term: Influenza immunizationEUCTR2008-005133-30-FIBaxter Innovations GmbH230
Active, not recruiting
Not Applicable
An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccineesEUCTR2007-006297-28-DEBavarian Nordic A/S